These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28094756)

  • 1. Treatment modifying factors of biologics for psoriatic arthritis: a systematic review and Bayesian meta-regression.
    Druyts E; Palmer JB; Balijepalli C; Chan K; Fazeli MS; Herrera V; Jansen JP; Park JJH; Kanters S; Reimold A
    Clin Exp Rheumatol; 2017; 35(4):681-688. PubMed ID: 28094756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.
    McInnes IB; Nash P; Ritchlin C; Choy EH; Kanters S; Thom H; Gandhi K; Pricop L; Jugl SM
    J Comp Eff Res; 2018 Nov; 7(11):1107-1123. PubMed ID: 30230361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Golimumab for the treatment of psoriatic arthritis.
    Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis.
    Lu C; Wallace BI; Waljee AK; Fu W; Zhang Q; Liu Y
    Semin Arthritis Rheum; 2019 Dec; 49(3):381-388. PubMed ID: 31272807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.
    Ruyssen-Witrand A; Perry R; Watkins C; Braileanu G; Kumar G; Kiri S; Nott D; Liu-Leage S; Hartz S; Sapin C
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32094304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of biologics on fatigue in psoriatic arthritis: A systematic literature review with meta-analysis.
    Reygaerts T; Mitrovic S; Fautrel B; Gossec L
    Joint Bone Spine; 2018 Jul; 85(4):405-410. PubMed ID: 29452303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis.
    Ungprasert P; Thongprayoon C; Davis JM
    Semin Arthritis Rheum; 2016 Feb; 45(4):428-38. PubMed ID: 26610638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
    Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
    J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N; Lee YC; Shah N; Harrison DJ
    Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Th17 Inhibitors in Active Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.
    Naik GS; Ming WK; Magodoro IM; Akinwunmi B; Dar S; Poulsen HE; Kristensen LE; Ellervik C
    Dermatology; 2017; 233(5):366-377. PubMed ID: 29258093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placebo response in relation to clinical trial design: a systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatment.
    Lamel SA; Myer KA; Younes N; Zhou JA; Maibach H; Maibach HI
    Arch Dermatol Res; 2012 Nov; 304(9):707-17. PubMed ID: 22843024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes.
    McInnes IB; Sawyer LM; Markus K; LeReun C; Sabry-Grant C; Helliwell PS
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35321874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Metaanalysis.
    Mourad A; Gniadecki R
    J Rheumatol; 2020 Jan; 47(1):59-65. PubMed ID: 30824641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic impact of biologic utilization patterns in patients with psoriatic arthritis.
    Schwartzman S; Li Y; Zhou H; Palmer JB
    Clin Rheumatol; 2017 Jul; 36(7):1579-1588. PubMed ID: 28474139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis.
    Song GG; Lee YH
    Z Rheumatol; 2018 Sep; 77(7):613-620. PubMed ID: 28791450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.